AbCellera Biologics Inc (ABCL) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ABCL.
| Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|
| 5 | $55 | $45 | $51.2 | $16.42 | 211.81% |
The Trend in the Analyst Price Target
Over the past 147 days, ABCL's average price target has gone down $4.6.
ABCL reports an average of 73.47% for its upside potential over the past 27 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-07-17 | 5 | 55 | 45 | 51.2 | 16.93 | 202.42% |
| 2021-07-10 | 5 | 55 | 45 | 51.2 | 19.37 | 164.33% |
| 2021-07-03 | 5 | 55 | 45 | 51.2 | 20.48 | 150% |
| 2021-06-26 | 5 | 55 | 45 | 51.2 | 20.74 | 146.87% |
| 2021-06-13 | 5 | 55 | 45 | 51.2 | 25.90 | 97.68% |
| 2021-06-05 | 5 | 55 | 45 | 51.2 | 25.97 | 97.15% |
| 2021-05-22 | 5 | 55 | 45 | 51.2 | 32.03 | 59.85% |
| 2021-05-15 | 5 | 55 | 45 | 51.2 | 31.75 | 61.26% |
| 2021-05-08 | 5 | 55 | 45 | 51.6 | 29.09 | 77.38% |
| 2021-04-25 | 5 | 55 | 45 | 52.2 | 29.33 | 77.97% |
| 2021-04-17 | 5 | 55 | 45 | 52.2 | 29.82 | 75.05% |
| 2021-04-10 | 5 | 55 | 45 | 52.4 | 28.35 | 84.83% |
| 2021-04-03 | 5 | 55 | 45 | 52.4 | 30.71 | 70.63% |
| 2021-03-20 | 5 | 61 | 52 | 55.8 | 31.20 | 78.85% |
| 2021-03-13 | 5 | 61 | 52 | 55.8 | 36.54 | 52.71% |
| 2021-03-06 | 5 | 61 | 52 | 55.8 | 28.61 | 95.04% |
| 2021-02-27 | 5 | 61 | 52 | 55.8 | 37.71 | 47.97% |
| 2021-02-20 | 5 | 61 | 52 | 55.8 | 44.07 | 26.62% |
| 2021-02-13 | 5 | 61 | 52 | 55.8 | 42.97 | 29.86% |
| 2021-02-06 | 5 | 61 | 45 | 54.4 | 46.55 | 16.86% |
| 2021-01-30 | 5 | 61 | 45 | 54.4 | 52.83 | 2.97% |
| 2021-01-23 | 5 | 59 | 45 | 51.4 | 50.50 | 1.78% |
| 2021-01-16 | 5 | 59 | 45 | 51.4 | 44.41 | 15.74% |
| 2021-01-09 | 5 | 59 | 45 | 51.4 | 39.72 | 29.41% |
ABCL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.3 | 2 | 3 | 0 | 0 | 0 | 5 |
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- ABCL has a higher upside potential (average analyst target price relative to current price) than 91.42% of all US stocks.
- AbCellera Biologics Inc's number of analysts covering the stock is greater than 6.65% of stocks in the large market cap category.
- AbCellera Biologics Inc's variance in analysts' estimates is less than 87% of stocks in the large market cap category.
- ABCL has a higher average analyst price target than 78.52% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to AbCellera Biologics Inc are VERU, KDMN and KZR.
Make investment decisions regarding ABCL using the data that counts. Try POWR Ratings for free.